Today, LifeCycle Pharma is listed on the Copenhagen Stock Exchange and is the seventy-first [1] company to join the Nordic Exchange this year and the thirteenth on the main market in Copenhagen.
LifeCycle Pharma A/S is an emerging pharmaceutical company with a full late-stage pipeline of proprietary product candidates. The company commenced operations in June 2002 as a spin-off from H. Lundbeck A/S. It bases its business on its proprietary MeltDose® technology which is used to create new versions of existing drugs.
Using the MeltDose® technology, LifeCycle Pharma A/S believes that it is able to develop products significantly faster and cheaper and with a higher success rate compared to the development of completely new drugs. For more information, please visit www.lcpharma.com
”We are very pleased to welcome yet another company to the Healthcare sector at the Nordic Exchange. LifeCycle Pharma is the fifth company to join this category this year”, says Jan Ovesen, President of the Copenhagen Stock Exchange.
A round lot of shares in LifeCycle Pharma, whose short name is LCP N, amounts to 200. LifeCycle Pharma is Mid Cap company included in the Healthcare sector.
[1]40 companies originate from the main lists of the Copenhagen, Stockholm, Helsinki, Riga, Tallinn and Vilnius stock exchanges and 31 from First North, of which 25 in Sweden and 6 in Denmark.
